

## NeoDynamics - Commercialization temporarily on hold

Redeye returns with a more detailed take on the Q2 report and concludes that the slow sales ramp-up is likely to spill over onto next year, by when FDA approval should be in place, opening the door for more substantial long-term sales growth. We also expect an equity issue by late H1 2023 rather than late 2023 /early 2024 and have adjusted our fair value range according to our capital raise assumptions.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**NeoDynamics - Commercialization temporarily on hold**